reconsideration of the amended claims is requested. An early allowance is earnestly sought.

Attached hereto as **APPENDIX A** is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

Respectfully submitted,

Dated: February 11, 2002

Lisa B. Kole
Patent Office Reg. No. 35,225

Carmella L. Stephens
Patent Office Reg. No. 41,328

BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, New York 10112-0228

Attorneys for Applicants
(212) 408-2539

APPENDIX A

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

On page 30, please delete the second full paragraph and replace it with the following paragraph:

--The anti-polycystin-1 antibody was raised in rabbits against a purified synthetic 31 amino acid peptide corresponding to amino acids 4161-4191 in the predicted intracellular portion of polycystin-1, proximal to the C-terminal: sequence LPSRSSRGSKVSPDVPPPSAGSDASHPSTSS (SEQ ID NO: 1). Antiserum specificity was confirmed by Elisa, immunoblot and immunocytochemical analyses, before and after affinity purification; by lack of staining with pre-immune sera and competition of immunoreaction by preadsorption with the appropriate peptide. Immunocytochemistry was carried out using an avidin-biotin-peroxidase system (Vectastain, Vector Laboratories) and aminoethylcarbazole as chromogen 9 (red color). Staining patterns were identical when carried out on frozen and paraformaldehyde (4%)-fixed material. 1:500 dilution of anti-polycystin-1 was used.--

IN THE CLAIMS:

Please cancel Claims 1-20, and insert the following new Claims:

--21. A method for identifying a compound capable of modulating polycystin-1 activity, comprising;

(a) contacting a test compound to a cell expressing a polycystin-1

protein wherein expression of said polycystin-1 protein results in an increase in cell adherence to type I collagen coated substrate;

(b) measuring cell adherence to type I collagen coated substrate; and

(c) comparing the level of cell adherence to type I collagen coated substrate obtained in (b) to the level of cell adherence to type I collagen coated substrate obtained in the presence of a vehicle control:

wherein if the level obtained in (b) differs from that obtained in the presence of a vehicle control, a compound capable of modulating polycystin-1 activity has been identified.

22. The method of Claim 21 wherein the cell is recombinantly engineered to express a mutant polycystin-1 protein.

23. The method of Claim 21 wherein the polycystin-1 protein is over expressed.

24. A method for identifying a compound capable of modulating polycystin-1 activity, comprising;

(a) contacting a test compound to a cell expressing a polycystin-1 protein wherein expression of said polycystin-1 protein results in an increase in apical expression of NaK-ATPase on the cell membrane;

(b) measuring an increase in apical expression of NaK-ATPase on the cell membrane; and

(c) comparing the level of an increase in apical expression of NaK-ATPase on the cell membrane obtained in (b) to the level of an increase in apical expression of NaK-ATPase on the cell membrane obtained in the presence of a vehicle

control:

wherein if the level obtained in (b) differs from that obtained in the presence of a vehicle control, a compound capable of modulating polycystin-1 activity has been identified.

25. The method of Claim 24 wherein the cell is recombinantly engineered to express a mutant polycystin-1 protein.

26. The method of Claim 24 wherein the polycystin-1 protein is over expressed.

27. A method for identifying a compound capable of modulating polycystin-1 activity, comprising;

(a) contacting a test compound to a cell expressing a polycystin-1 protein wherein expression of said polycystin-1 protein results in an increased expression of ß-2-NaKATPase within the cell;

(b) measuring increased expression of ß-2-NaKATPase within the cell; and

(c) comparing the level of increased expression of ß-2-NaKATPase within the cell obtained in (b) to the level of increased expression of ß-2-NaKATPase within the cell obtained in the presence of a vehicle control:

wherein if the level obtained in (b) differs from that obtained in the presence of a vehicle control, a compound capable of modulating polycystin-1 activity has been identified.

28. The method of Claim 27 wherein the cell is recombinantly engineered to express a mutant polycystin-1 protein.

29. The method of Claim 27, 28 or 29 wherein the polycystin-1 protein is over expressed.

30. The method of Claim 7, 8 or 9 wherein the expression of ß-2-NaK-ATPase within the cell is measured using an anti-ß-2-NaK-ATPase antibody.

31. A method for identifying a compound capable of modulating polycystin-1 activity, comprising;

(a) contacting a test compound to a cell expressing a polycystin-1 protein wherein expression of said polycystin-1 protein results in a decreased incorporation of focal adhesion kinase into focal adhesion complexes;

(b) measuring a decreased incorporation of focal adhesion kinase into focal adhesion complexes; and

(c) comparing the level of a decreased incorporation of focal adhesion kinase into focal adhesion complexes obtained in (b) to the level of a decreased incorporation of focal adhesion kinase into focal adhesion complexes obtained in the presence of a vehicle control:

wherein if the level obtained in (b) differs from that obtained in the presence of a vehicle control, a compound capable of modulating polycystin-1 activity has been identified.

32. The method of Claim 31 wherein the cell is recombinantly engineered to express a mutant polycystin-1 protein.

33. The method of Claim 32 wherein the polycystin-1 protein is over expressed.

34. The method of Claim 31, 32, or 33 wherein the incorporation of focal adhesion kinase into focal adhesion complexes is measured using an anti-focal adhesion kinase antibody.

35. The method of Claim 31 wherein the cell expressing the polycystin-1 protein further comprises an epitope tagged focal adhesion kinase protein.

36. The method of Claim 22, 25, 28 or 32 wherein the recombinantly engineered cell comprises an epitope tagged polycystin-1 interacting protein.

37. The method of Claim 2, 3, 5, 6, 8, 9, 12 or 13 wherein the polycystin-1 protein is epitope tagged. --